XML 28 R20.htm IDEA: XBRL DOCUMENT
v3.26.1

Summary of Significant Accounting Policies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Accounting Policies [Abstract] |
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash | The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:
|  | Six Months Ended June 30, |
|  | 2026 |  |  | 2025 |
|  | (In thousands) |
Cash and cash equivalents |  | $ | 59,915 |  |  | $ | 44,771 |
Restricted cash |  |  | 1,846 |  |  |  | 1,846 |
Total cash, cash equivalents, and restricted cash |  | $ | 61,761 |  |  | $ | 46,617 |
Summary of Segment Profit or Loss Including Significant Segment Expenses | The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
Collaboration revenue |  | $ | 3,320 |  |  | $ | 7,874 |  |  | $ | 4,366 |  |  | $ | 11,548 |
Less: |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 7,067 |  |  |  | 14,262 |  |  |  | 15,315 |  |  |  | 30,819 |
Lab expenses and outside research services |  |  | 4,809 |  |  |  | 2,903 |  |  |  | 8,256 |  |  |  | 6,127 |
Clinical supply costs |  |  | 3,028 |  |  |  | 3,873 |  |  |  | 4,407 |  |  |  | 6,947 |
Clinical trials |  |  | 1,371 |  |  |  | 7,081 |  |  |  | 4,755 |  |  |  | 14,094 |
Support functions |  |  | 6,123 |  |  |  | 7,701 |  |  |  | 12,423 |  |  |  | 15,987 |
Other segment expenses(a) |  |  | 5,315 |  |  |  | 6,192 |  |  |  | 8,522 |  |  |  | 16,407 |
Total operating expenses |  |  | 27,713 |  |  |  | 42,012 |  |  |  | 53,678 |  |  |  | 90,381 |
Loss from operations |  |  | (24,393 | ) |  |  | (34,138 | ) |  |  | (49,312 | ) |  |  | (78,833 | )
Other income, net |  |  | 1,533 |  |  |  | 3,614 |  |  |  | 3,522 |  |  |  | 7,838 |
Income tax |  |  | 130 |  |  |  | — |  |  |  | 130 |  |  |  | — |
Segment and consolidated loss |  | $ | (22,990 | ) |  | $ | (30,524 | ) |  | $ | (45,920 | ) |  | $ | (70,995 | )
(a) Other segment expenses include consultants & contractor expense, contra-R&D expense for GSK collaboration, depreciation expense, impairment loss, restructuring expense, and stock-based compensation expense.

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details
Name: | us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration